

# Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

## SK-MEL-28

RRID:CVCL\_0526

Type: Cell Line

### Proper Citation

RRID:CVCL\_0526

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0526](https://web.expasy.org/cellosaurus/CVCL_0526)

**Proper Citation:** RRID:CVCL\_0526

**Description:** Cell line SK-MEL-28 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Cutaneous melanoma

**Defining Citation:** [PMID:313568](#), [PMID:327080](#), [PMID:978138](#), [PMID:1067619](#), [PMID:1716514](#), [PMID:2041050](#), [PMID:2068080](#), [PMID:2983346](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6197381](#), [PMID:6203018](#), [PMID:6349783](#), [PMID:6582512](#), [PMID:6864164](#), [PMID:6933476](#), [PMID:7017212](#), [PMID:7175440](#), [PMID:7718330](#), [PMID:7999427](#), [PMID:8631022](#), [PMID:9331090](#), [PMID:9354451](#), [PMID:9466661](#), [PMID:9598804](#), [PMID:10700174](#), [PMID:10766161](#), [PMID:11016658](#), [PMID:11121133](#), [PMID:12068308](#), [PMID:12479222](#), [PMID:14692828](#), [PMID:14871852](#), [PMID:15009714](#), [PMID:15299072](#), [PMID:15467732](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:17260012](#), [PMID:17308088](#), [PMID:17363583](#), [PMID:17516929](#), [PMID:18277095](#), [PMID:18790768](#), [PMID:19147755](#), [PMID:19372543](#), [PMID:19799798](#), [PMID:20041153](#), [PMID:20164919](#), [PMID:20406486](#), [PMID:21424129](#), [PMID:21725359](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23285177](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24576830](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25950383](#), [PMID:25960936](#), [PMID:26405815](#), [PMID:26589293](#), [PMID:26673621](#), [PMID:27087056](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29492214](#), [PMID:30674989](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

**Comments:** Characteristics: Lightly pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia -

CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** SK-MEL-28

**Synonyms:** SK-Mel-28, SK.MEL.28, SK-MEL 28, SK MEL-28, SK MEL 28, SK Mel 28, SKMel-28, SKMEL-28, SK-MEL28, SK-Mel28, SK Mel28, SKMEL28, SKMel28, SKmel28, SKML-28, SK28, AU-Mel, P-36, P36

**Cross References:** BTO:BTO\_0002131, CLO:CLO\_0009043, EFO:EFO\_0003081, MCCL:MCC:0000426, CLDB:cl4321, CLDB:cl4954, AddexBio:C0020001/66, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-72, BCRJ:0289, BioSample:SAMN03470899, BioSample:SAMN03472092, BioSample:SAMN03472754, BioSample:SAMN10987689, cancercellines:CVCL\_0526, CancerTools:161917, Cell\_Model\_Passport:SIDM00081, CGH-DB:9317-4, ChEMBL-Cells:ChEMBL3308494, ChEMBL-Targets:ChEMBL614919, CLS:300337, Cosmic:686472, Cosmic:686476, Cosmic:687442, Cosmic:706106, Cosmic:721824, Cosmic:851050, Cosmic:874384, Cosmic:874446, Cosmic:875887, Cosmic:886831, Cosmic:888846, Cosmic:897491, Cosmic:898252, Cosmic:905230, Cosmic:905954, Cosmic:928748, Cosmic:932712, Cosmic:933135, Cosmic:974072, Cosmic:974262, Cosmic:1006554, Cosmic:1007156, Cosmic:1022271, Cosmic:1045407, Cosmic:1047687, Cosmic:1054859, Cosmic:1067227, Cosmic:1092633, Cosmic:1102386, Cosmic:1109809, Cosmic:1132589, Cosmic:1155280, Cosmic:1155570, Cosmic:1175872, Cosmic:1183772, Cosmic:1187579, Cosmic:1221590, Cosmic:1238109, Cosmic:1295337, Cosmic:1303055, Cosmic:1305368, Cosmic:1312350, Cosmic:1425350, Cosmic:1458966, Cosmic:1459645, Cosmic:1477319, Cosmic:1477408, Cosmic:1507598, Cosmic:1598350, Cosmic:1665022, Cosmic:1669144, Cosmic:1995635, Cosmic:1998476, Cosmic:2159448, Cosmic:2479251, Cosmic:2560253, Cosmic:2651877, Cosmic-CLP:905954, DepMap:ACH-000615, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:905954, GEO:GSM2115, GEO:GSM50205, GEO:GSM50267, GEO:GSM156050, GEO:GSM171012, GEO:GSM188226, GEO:GSM188256, GEO:GSM188315, GEO:GSM206543, GEO:GSM228378, GEO:GSM274690, GEO:GSM276739, GEO:GSM743468, GEO:GSM750825, GEO:GSM784506, GEO:GSM799357, GEO:GSM799420, GEO:GSM844690, GEO:GSM847116, GEO:GSM887584, GEO:GSM888667, GEO:GSM952581, GEO:GSM1138790, GEO:GSM1153427, GEO:GSM1153428, GEO:GSM1181282, GEO:GSM1181283, GEO:GSM1588919, GEO:GSM1670439, GEO:GSM1671969, GEO:GSM1671970, GEO:GSM1671974, GEO:GSM1671983, GEO:GSM1671986, GEO:GSM1671991, GEO:GSM1671996, GEO:GSM1672002, GEO:GSM1672006, GEO:GSM1672032, GEO:GSM1672043, GEO:GSM1672047, GEO:GSM1672049, GEO:GSM1672050, GEO:GSM1672054, GEO:GSM1672056, GEO:GSM1672060, GEO:GSM1672061, GEO:GSM2124651, GEO:GSM3039512, IARC\_TP53:26113, ICLC:HTL99010, LiGeA:CCLE\_529, LINCS\_HMS:51101, LINCS\_LDP:LCL-2092, NCI-DTP:SK-MEL-28, PharmacDB:SKMEL28\_1396\_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD007000, PRIDE:PXD030304, Progenetix:CVCL\_0526, PubChem\_Cell\_line:CVCL\_0526, RCB:RCB1930, SKY/M-FISH/CGH:2745, TKG:TKG 0333, Wikidata:Q54954013

**ID:** CVCL\_0526

**Record Creation Time:** 20220427T221546+0000

**Record Last Update:** 20260829T235929+0000

---

## Ratings and Alerts

No rating or validation information has been found for SK-MEL-28.

**Warning:** Discontinued: RCB; RCB1930

Characteristics: Lightly pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Warning:** Discontinued: TKG; TKG 0333

Characteristics: Lightly pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 919 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Deng C, et al. (2026) Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(26), e20917.

Lan TH, et al. (2026) A single-component optogenetic toolkit for reversible visualization and programmable control of microtubule dynamics. Cell reports methods, 101532.

Zhou Z, et al. (2026) The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLoS biology, 24(1), e3003603.

Shi HZ, et al. (2026) BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(28), e14590.

Arroyo Villora S, et al. (2026) A Bioinformatics and Wet-Lab-Based Pipeline Identifies CLDN10 and GJB2 as Epigenetically Silenced Tumor Suppressor Genes in Cutaneous Melanoma. International journal of molecular sciences, 27(5).

- Tang X, et al. (2026) Mathematical modeling of ribosome competition informs testable treatment strategies for drug-tolerant cancer persister cells. *iScience*, 29(4), 115493.
- Cinel VDP, et al. (2026) Proteasomal degradation of intracellularly expressed Amblyomin-X limits suicide gene therapy potential in melanoma cells. *FEBS open bio*, 16(8), 1602.
- Ramírez-Sánchez A, et al. (2026) Metabolic buffering restricts phenotype switching in melanoma. *The EMBO journal*.
- de Blas A, et al. (2026) Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. *Cancer research*, 86(12), 2896.
- Cobb DA, et al. (2026)  $\gamma$ 3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. *Molecular cancer therapeutics*, 25(7), 1181.
- Mao C, et al. (2026) Driver Mutation Subtypes Differentially Shape Immune Evasion Landscapes in Melanoma: An AI-Driven Inflammatory Pathway Model Implicating CCNE1. *Human mutation*, 2026, 6776070.
- Berra C, et al. (2026) AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma. *Cell death discovery*, 12(1).
- Ibrahim M, et al. (2026) NF1 Loss Remodels Tumor Niches for Immune Evasion. *bioRxiv : the preprint server for biology*.
- Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.
- Zhao T, et al. (2025) Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming. *Cell metabolism*, 37(8), 1667.
- Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(47), e11349.
- Vax E, et al. (2025) A novel Frizzled 7 antibody disrupts the Wnt pathway and inhibits Wilms tumor growth. *Frontiers in bioengineering and biotechnology*, 13, 1641137.
- Iozzo M, et al. (2025) Sex-related changes in lactate dehydrogenase A expression differently impact the immune response in melanoma. *The FEBS journal*, 292(12), 3056.
- Wiedmer T, et al. (2025) Metabolic mapping of the human solute carrier superfamily. *Molecular systems biology*, 21(6), 560.
- Deuschmeyer VE, et al. (2025) SIAH3 is frequently epigenetically silenced in cancer and regulates mitochondrial metabolism. *International journal of cancer*, 156(2), 353.